Pacific Biosciences Of California (PACB) Non-Current Deffered Revenue (2011 - 2026)
Pacific Biosciences Of California (PACB) posted quarterly Non-Current Deffered Revenue of $3.6 million for Q1 2026, down 39.3% year-over-year from $5.9 million in Q1 2025, and down 9.54% quarter-over-quarter from $3.9 million in Q4 2025.
Pacific Biosciences Of California (PACB) Non-Current Deffered Revenue (2011 - 2026) Analysis & Trends
Pacific Biosciences Of California's Non-Current Deffered Revenue history runs 16 years deep, the most recent figure standing at $3.6 million for Q1 2026.
- In Q1 2026, Non-Current Deffered Revenue fell 39.3% year-over-year to $3.6 million; the TTM figure through Mar 2026 stood at $3.6 million (down 39.3% YoY), while the FY2025 annual figure was $3.9 million, down 33.41% from the prior year.
- Non-Current Deffered Revenue for Q1 2026 stood at $3.6 million, down from $3.9 million in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $25.2 million in Q1 2022, with the low at $1.8 million in Q3 2022.
- The 5-year median for Non-Current Deffered Revenue is $5.1 million (2023), against an average of $5.6 million.
- Peak annual rise in Non-Current Deffered Revenue reached 343.92% in 2022, while the deepest fall reached 92.84% in 2022.
- Pacific Biosciences Of California's Non-Current Deffered Revenue stood at $1.8 million in 2022, then soared by 208.25% to $5.5 million in 2023, then rose by 6.69% to $5.9 million in 2024, then plunged by 33.41% to $3.9 million in 2025, then decreased by 9.54% to $3.6 million in 2026.
- Business Quant data shows PACB's Non-Current Deffered Revenue at $3.6 million in Q1 2026, $3.9 million in Q4 2025, and $4.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | - |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | - |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | - |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | - |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | - |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | - |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | - |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | 539.34 Mn |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | - |
| 10 | Pacific Biosciences Of California | 381.79 Mn | 144.92 Mn | 12.64 Mn | 3.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.34 Mn |
| Mar 31, 2026 | 3.55 Mn |
| Dec 31, 2025 | 3.93 Mn |
| Sep 30, 2025 | 4.40 Mn |
| Jun 30, 2025 | 5.71 Mn |
| Mar 31, 2025 | 5.86 Mn |
| Dec 31, 2024 | 5.90 Mn |
| Sep 30, 2024 | 5.50 Mn |
| Jun 30, 2024 | 5.70 Mn |
| Mar 31, 2024 | 6.10 Mn |
| Dec 31, 2023 | 5.53 Mn |
| Sep 30, 2023 | 5.05 Mn |
| Jun 30, 2023 | 4.99 Mn |
| Mar 31, 2023 | 1.85 Mn |
| Dec 31, 2022 | 1.79 Mn |
| Sep 30, 2022 | 1.76 Mn |
| Jun 30, 2022 | 1.83 Mn |
| Mar 31, 2022 | 25.25 Mn |
| Dec 31, 2021 | 25.05 Mn |
| Jun 30, 2021 | 10.16 Mn |